Trials / Approved For Marketing
Approved For MarketingNCT00889135
Long Term Treatment With L-DOPS
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Vanderbilt University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to supply L-DOPS (droxidopa) on a long term basis to patients with a genetic form of profound orthostatic hypotension, most commonly DBH deficiency. It also allows us to collect medical history information on this small population of patients that would allow us to determine if there are any complications from this type of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | droxidopa | Droxidopa (L-DOPS) comes in capsule form, 100 mg or 200 mg strength and is usually administered 2 - 3 times per day. It would be taken indefinitely to improve symptoms of orthostatic hypotension |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2009-04-28
- Last updated
- 2016-10-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00889135. Inclusion in this directory is not an endorsement.